Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 14:17:11790.
doi: 10.3389/or.2023.11790. eCollection 2023.

Challenges of FGFR2 Testing in Gastric Cancer

Ilya Tsimafeyeu #  1 , Grigory Raskin #  2
Affiliations

Challenges of FGFR2 Testing in Gastric Cancer

Ilya Tsimafeyeu et al. Oncol Rev. .
No abstract available

Keywords: amplification; expression; fibroblast growth factor receptor 2; gastric cancer; heterogeneity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Intratumor heterogeneity of FGFR2 IHC expression in the primary tumor (A,C), which led to the appearance of FGFR2-negative metastasis (B) and FGFR2-positive metastasis (D) in the same patient.
See this image and copyright information in PMC

References

    1. Tsimafeyeu I, Rahib L. The Future Landscape of Cancer Incidence and Mortality Until 2036 in the Russian Federation. J Clin Oncol (2022) 40(16):e22518. 10.1200/JCO.2022.40.16_suppl.e22518 - DOI
    1. NCCN. NCCN Guidelines: Gastric Cancer, Version 2.2023 (2023).
    1. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab Plus mFOLFOX6 in Patients With CLDN18.2-Positive, HER2-Negative, Untreated, Locally Advanced Unresectable or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (SPOTLIGHT): A Multicentre, Randomised, Double-Blind, Phase 3 Trial. The Lancet (2023) 401(10389):1655–68. 10.1016/S0140-6736(23)00620-7 - DOI - PubMed
    1. Katoh M. Fibroblast Growth Factor Receptors as Treatment Targets in Clinical Oncology. Nat Rev Clin Oncol (2019) 16(2):105–22. 10.1038/s41571-018-0115-y - DOI - PubMed
    1. Lengyel CG, Hussain S, Seeber A, Jamil Nidhamalddin S, Trapani D, Habeeb BS, et al. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? Life (Basel) (2022) 12(1):81. 10.3390/life12010081 - DOI - PMC - PubMed